Page results
-
Patient Advice and Liaison Service (PALS)
-
As an organisation, UCLH needs to minimise the environmental impact of our buildings and the energy they use and maximise our use of any technology available to support these changes. This page outlines our progress to date.
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
UCLH Charity is delighted to announce a generous £1.5 million donation from the Bukhman Philanthropies.
-
UCLH is to host to a new collaboration researching patient safety, after being awarded £3million in funding.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
Ensuring that UCLH staff understand the urgency of the climate crisis and support our net zero programme is crucial if we want to be successful in reaching our goal of net zero carbon emissions by 2031. Our patients must be kept informed of changes and we must work closely with other NHS organisations, including NHS England, if we are to deliver a successful programme. This page documents our progress to date.
-
A breathing aid that can help keep Covid-19 patients out of intensive care, adapted by mechanical engineers at UCL and clinicians at UCLH working with Mercedes-AMG High Performance Powertrains (Mercedes-AMG HPP), has been approved for use in the NHS.
-
The artist Caroline Walker, whose work was featured in The Guardian at the weekend, created some of the paintings being shown in her current solo exhibition, during an artist residency at UCLH in 2021.
-
A smartphone app that identifies severe neonatal jaundice could provide a cheaper alternative to expensive screening procedures, according to a study by UCLH, UCL and the University of Ghana.
File results
-
FOI/2024/0143 - Individuals arriving at A&E not in an ambulance
-
FOI/2024/0144 - Breast cancer treatment
-
FOI/2024/0148 - Cleaning audit system at Trust
-
FOI/2024/0149 - National Hospital for Neurology and Neurosurgery (NHNN) admissions 2018-2023
-
FOI/2024/0155 - Immunotherapy treatments for lung cancer
-
FOI/2024/0162 - Various technology systems/ services used at Trust
-
FOI/2024/0163 - Renal cell carcinoma and melanoma treatments
-
FOI/2024/0166 - Recruitment systems/CRM platform
-
FOI/2024/0171 - Dermatology consultants
-
FOI/2024/0172 - Patients excluded from care at the Trust 2010-2023